These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11733188)

  • 21. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes.
    Kasparkova J; Farrell N; Brabec V
    J Biol Chem; 2000 May; 275(21):15789-98. PubMed ID: 10747955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM; Whitehead JP; Lippard SJ
    Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures.
    Ugrinova I; Pasheva EA; Armengaud J; Pashev IG
    Biochemistry; 2001 Dec; 40(48):14655-60. PubMed ID: 11724579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA.
    Farid RS; Bianchi ME; Falciola L; Engelsberg BN; Billings PC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):532-9. PubMed ID: 8975778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.
    Hoffmann JS; Locker D; Villani G; Leng M
    J Mol Biol; 1997 Jul; 270(4):539-43. PubMed ID: 9245584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J; Novakova O; Farrell N; Brabec V
    Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recognition of platinum-DNA adducts by HMGB1a.
    Ramachandran S; Temple B; Alexandrova AN; Chaney SG; Dokholyan NV
    Biochemistry; 2012 Sep; 51(38):7608-17. PubMed ID: 22950413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
    Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin.
    Pil PM; Lippard SJ
    Science; 1992 Apr; 256(5054):234-7. PubMed ID: 1566071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair protein.
    Elder RM; Jayaraman A
    Biophys J; 2012 May; 102(10):2331-8. PubMed ID: 22677386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].
    Brabec V; Vrána O; Nováková O; Kleinwächter V; Intini FP; Coluccia M; Natile G
    Nucleic Acids Res; 1996 Jan; 24(2):336-41. PubMed ID: 8628659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the Interactions of High-Mobility Group of Protein Domain B1 with DNA Adducts Generated by Platinum Anticancer Molecules Using In Silico Approaches.
    Misra G; Gupta S; Jabalia N
    Interdiscip Sci; 2018 Sep; 10(3):476-485. PubMed ID: 27900730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM; Mikata Y; He Q; Lippard SJ
    Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.